Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2086 to 2100 of 8933 results

  1. Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

    Awaiting development Reference number: GID-TA10723 Expected publication date: TBC

  2. Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

    Awaiting development Reference number: GID-TA10773 Expected publication date: TBC

  3. Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

    Awaiting development Reference number: GID-TA10776 Expected publication date: TBC

  4. Timrepigene emparvovec for treating choroideremia [ID3916]

    Awaiting development Reference number: GID-TA10787 Expected publication date: TBC

  5. Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

    Awaiting development Reference number: GID-TA10431 Expected publication date: TBC

  6. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development Reference number: GID-TA10439 Expected publication date: TBC

  7. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development Reference number: GID-TA10446 Expected publication date: TBC

  8. Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

    Awaiting development Reference number: GID-TA10453 Expected publication date: TBC

  9. Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]

    In development Reference number: GID-TA10497 Expected publication date: TBC

  10. Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]

    In development Reference number: GID-TA10606 Expected publication date: TBC

  11. Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

    Awaiting development Reference number: GID-TA10657 Expected publication date: TBC

  12. Sotagliflozin for treating type 2 diabetes [ID1657]

    Awaiting development Reference number: GID-TA10665 Expected publication date: TBC

  13. Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

    Awaiting development Reference number: GID-TA10683 Expected publication date: TBC

  14. Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

    Awaiting development Reference number: GID-TA10684 Expected publication date: TBC

  15. Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

    Awaiting development Reference number: GID-TA10685 Expected publication date: TBC